Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Stockhead TV
Break it Down: Quick access to quick ED fix from LTR Pharma
Health & Biotech
LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment
Health & Biotech
Health Check: The robots are taking over biotech stock selection
Health & Biotech
Renerve all set to become only the second nerve-repair stock on the ASX
Health & Biotech
LTR Pharma joins with leading men’s health group to launch telehealth platform
Health & Biotech
Health Check: It’s a small world after all for global microcap index additions LTR Pharma and EZZ Life Science
Health & Biotech
ASX Quarterly Health Wrap: Lift-off for ED nasal spray and record users for pregnancy-monitoring platform
Health & Biotech
LTR Pharma’s ED treatment SPONTAN outperforms with 470% faster absorption
Health & Biotech
Health Check: Thirsty Chimeric goes to the well for funding top-up
Health & Biotech
ASX stocks leading clinical trials in Australia
Health & Biotech
Bio Curious: Nerve repair house plans to break the IPO drought
Health & Biotech
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
News
ASX August Winners: The 50 best stocks in a volatile month for markets
Stockhead TV
Long Shortz with LTR Pharma: Erectile dysfunction help just a spray away
Health & Biotech
ASX Health Stocks: Lift off for LTR Pharma’s ED therapy under TGA scheme
News
